These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17963033)

  • 21. Emerging role of NET inhibitors in cardiovascular diseases.
    Jayaseelan VP; Paramasivam A
    Hypertens Res; 2020 Dec; 43(12):1459-1461. PubMed ID: 32733104
    [No Abstract]   [Full Text] [Related]  

  • 22. Leptin and the cardiovascular system - a target for therapeutic interventions.
    Beltowski J
    Curr Pharm Des; 2014; 20(4):601-2. PubMed ID: 23688018
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic potential of neuregulin-1 in cardiovascular disease.
    Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiovascular pharmacology (V). Pharmacological interactions in the patient on immunodepressant treatment].
    Alonso Pulpón L; Anguita Sánchez M
    Rev Esp Cardiol; 1994 Oct; 47(10):687-98. PubMed ID: 7991923
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology.
    Sun HJ; Wu ZY; Cao L; Zhu MY; Nie XW; Huang DJ; Sun MT; Bian JS
    Pharmacol Res; 2020 Sep; 159():104961. PubMed ID: 32474086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Effects of Flavonoids.
    Sánchez M; Romero M; Gómez-Guzmán M; Tamargo J; Pérez-Vizcaino F; Duarte J
    Curr Med Chem; 2019; 26(39):6991-7034. PubMed ID: 30569843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.
    Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S
    Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of pharmacotherapy of osteoporosis in cardiology patients.
    Zapolski T; Wysokiński A
    Cardiol J; 2010; 17(4):335-43. PubMed ID: 20690088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology and pharmacotherapy of cardiovascular drugs in patients with chronic renal disease.
    Barbour MM; McKindley DS
    Semin Nephrol; 2001 Jan; 21(1):66-78. PubMed ID: 11172561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Cardiovascular Therapeutics. Cambridge, MA, USA, June 10-11, 2003.
    Zavoico GB
    Cardiovasc Drug Rev; 2003; 21(3):246-53. PubMed ID: 14582482
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular pharmacology in the post-blockbuster era.
    Brandes RP
    Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
    [No Abstract]   [Full Text] [Related]  

  • 32. Gp IIb/IIIa antagonists. Summary and table.
    Coleman SG; Duff R
    Drugs R D; 1999 May; 1(5):371-3. PubMed ID: 10566066
    [No Abstract]   [Full Text] [Related]  

  • 33. Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases.
    Frangieh J; Rima M; Fajloun Z; Henrion D; Sabatier JM; Legros C; Mattei C
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Annual meeting of the American Heart Association. Dallas, Texas, USA, 13-16 November 2005.
    von Haehling S; Sandek A; Thum T
    Expert Opin Investig Drugs; 2006 May; 15(5):563-9. PubMed ID: 16634694
    [No Abstract]   [Full Text] [Related]  

  • 35. European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition.
    Atar D
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):3-4. PubMed ID: 28062654
    [No Abstract]   [Full Text] [Related]  

  • 36. Abstracts of the 8th International Congress of Update in Cardiology and Cardiovascular Surgery. March 1-4, 2012. Antalya, Turkey.
    Heart Surg Forum; 2012 Feb; 15 Suppl 1():S1-145. PubMed ID: 22491139
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology.
    Salabei JK; Conklin DJ
    Cardiovasc Toxicol; 2013 Sep; 13(3):220-9. PubMed ID: 23408289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach.
    Bisi A; Gobbi S; Belluti F; Rampa A
    Curr Med Chem; 2013; 20(13):1759-82. PubMed ID: 23410171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving current goals in prevention and treatment of vascular disease: an update.
    Catapano AL; Elisaf MS; Florentin M; Mikhailidis DP; Kostapanos MS
    Curr Pharm Des; 2013; 19(21):3749-52. PubMed ID: 23286439
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiovascular pharmacotherapy.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):1. PubMed ID: 29315398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.